In combination studies using established PTEN/TP53 null LuCaP 136 tumors, ganetespib added to castration compared to castration alone, led to deeper initial tumor regressions, and delayed progression to growth in a castrate environment (Fig. 6). This evidence concerns the gene TP53 and neoplasm.